Physician profile
Devan Elayna Scott
NPI 1932812435
$3,315.09
in general payments reported to CMS, 2019-2025
23 companies · $1,157 in 2025
The $1,157 reported for 2025 was more than what 87% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,593 · 2024: $566 · 2025: $1,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,020 · Education: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,020.21 |
| Education | $294.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $479.99 | 2023-2025 | Cresemba, Xospata |
| Syndax Pharmaceuticals, INC. | $310.03 | 2025 | Revuforj |
| Astrazeneca Pharmaceuticals LP | $307.43 | 2023-2025 | Calquence |
| Daiichi Sankyo INC. | $253.84 | 2023-2024 | Vanflyta, Enhertu |
| Incyte Corporation | $251.92 | 2023-2025 | Jakafi, Niktimvo |
| Abbvie INC. | $178.26 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $167.45 | 2023 | Imbruvica, Epkinly |
| Lilly USA, LLC | $165.53 | 2023-2025 | Jaypirca |
| Teleflex LLC | $153.98 | 2025 | Arrow |
| Pharmaessentia USA Corporation | $152.66 | 2023-2024 | Besremi |
| Celgene Corporation | $142.49 | 2023-2024 | Reblozyl |
| Adaptive Biotechnologies Corporation | $117.72 | 2025 | Clonoseq |
| Merck Sharp & Dohme LLC | $110.07 | 2023-2025 | Dificid, Zerbaxa, Recarbrio |
| E.R. Squibb & Sons, L.L.C. | $107.31 | 2023 | Reblozyl |
| Sobi, INC | $106.94 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $82.47 | 2023 | Blincyto, Kyprolis |
| Novartis Pharmaceuticals Corporation | $56.95 | 2023 | |
| Glaxosmithkline, LLC. | $32.61 | 2025 | Ojjaara |
| Blueprint Medicines Corporation | $32.22 | 2024 | Ayvakit |
| Beigene USA, INC. | $28.09 | 2024 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $27.02 | 2023 | Rezlidhia, Tavalisse |
| Cti Biopharma Corp. | $27.00 | 2023 | Vonjo |
| Taiho Oncology, INC. | $23.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devan Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.